20-Mar-2018 - Harvard University

Harvard bioengineers' biomaterial-based cancer immunotherapies to be developed by Novartis

The Wyss Institute for Biologically Inspired Engineering at Harvard University and the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) announced today that Novartis will have access to commercially develop their therapeutic, biomaterial-based, cancer vaccine technology that promotes anti-cancer immunity. Under a licensing agreement spearheaded by Harvard's Office of Technology Development (OTD), Novartis will have worldwide rights, in target-limited applications, to develop and translate this approach to treat patients.

Unlike cell-based cancer immunotherapies that rely on manipulating immune cells outside of the body and transferring them into patients, the implantable immuno-material approach activates endogenous immune cells inside the body to launch an attack on the patient's own cancer. The novel technique was developed, incubated, and advanced at the Wyss Institute and SEAS by David Mooney, Wyss Core Faculty member, lead of the Immuno-Materials initiative at the Wyss Institute, and Robert P. Pinkas Family Professor of Bioengineering at SEAS.

The first-generation therapy consists of a porous scaffold material made from a widely used biodegradable medical polymer infused with inactivated antigens from the patient's tumor cells, as well as immunostimulatory molecules that attract dendritic cells of the immune system to the immuno-material site and activate them to stimulate a host response. After activation, the dendritic cells home to nearby lymph nodes to orchestrate anti-tumor responses throughout the body.

"This work resulted from a remarkable cross-disciplinary effort using the combined expertise of bioengineers, cancer biologists and immunologists," said Mooney. "We have demonstrated that these biomaterials can be easily delivered to patients, provide sustained and local release of immune-modulating factors, and bypass the need for modification of cells outside the body. This concept has led to a very promising platform for cancer immunotherapy."

In 2013, the Wyss Institute and the Dana-Farber Cancer Institute (DFCI) initiated a Phase I clinical trial at DFCI to test the safety of the first of these implantable, immuno-material-based cancer vaccines in patients with melanoma, a lethal form of skin cancer. The trial, led by F. Stephen Hodi, Jr., M.D., Director of DFCI's Melanoma Center and Professor of Medicine at Harvard Medical School (HMS), is still ongoing with many of its original patients.

The trial followed extensive preclinical studies performed by a collaborative team headed by Mooney and Glenn Dranoff, M.D., who at the time was a Wyss Institute Associate Faculty member and co-leader of Dana Farber's Cancer Vaccine Center. The team demonstrated that the cancer vaccine could potentially shrink or eradicate multiple types of tumors, in addition to providing prophylactic protection, in various animal models. Dranoff is now Global Head of Exploratory Immuno-Oncology at the Novartis Institutes for Biomedical Research.

Novartis has also established a collaboration agreement with the Wyss Institute to further develop biomaterial systems for its portfolio of second-generation immuno-oncology therapies.

"When we initiated this cancer vaccine program at the Wyss Institute, it was strike zone for what we wanted to pursue - a research project conceived by our visionary faculty that was high-risk and required a highly collaborative and interdisciplinary effort but had the potential to bring about a transformative advance in clinical care. Then, with the vision and collaborative support of another institutional member of the Wyss Institute consortium, the Dana-Farber Cancer Institute, we made the decision to co-fund a Phase I clinical trial inside academia, which was really pushing the envelope. Thus, this agreement is extremely exciting for us because it validates our innovation model, but even more importantly, it will bring an exciting new therapeutic modality into the clinic for patients with many different types of cancer," said Wyss Institute Founding Director Donald Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at HMS and the Vascular Biology Program at Boston Children's Hospital, as well as Professor of Bioengineering at SEAS.

Facts, background information, dossiers
  • Novartis
  • Harvard University
  • cancer immunotherapies
  • lymph nodes
  • therapeutic polymers
  • cancer vaccines
  • biodegradable polymers
More about Harvard University
  • News

    Building a better botox

    Botulinum toxins -- a.k.a. botox -- have a variety of uses in medicine: to treat muscle overactivity in overactive bladder, to correct misalignment of the eyes in strabismus, for neck spasms in cervical dystonia, and more. Two botulinum toxins, types A and B, are FDA-approved and widely use ... more

    Separating Drugs with MagLev

    The composition of suspicious powders that may contain illicit drugs can be analyzed using a quick and simple method called magneto-Archimedes levitation (MagLev), according to a new study published in the journal Angewandte Chemie. A team of scientists at Harvard University, USA, has devel ... more

    Combination gene therapy treats multiple age-related diseases

    As we age, our bodies tend to develop diseases like heart failure, kidney failure, diabetes, and obesity, and the presence of any one disease increases the risk of developing others. Traditional drug development targets only one condition per drug, largely ignoring the interconnectedness of ... more

  • Videos

    A diamond radio receiver

    Researchers from the Harvard John A. Paulson School of Engineering and Applied Sciences have made the world’s smallest radio receiver – built out of an assembly of atomic-scale defects in pink diamonds. This tiny radio — whose building blocks are the size of two atoms — can withstand extrem ... more

    Timing Cancer Treatment

    There may be an ideal waiting period for delivering multiple cancer drugsResearchers led by members of the Department of Systems Biology at Harvard Medical School had been studying how silencing MDMX, an oncogene, affected the dynamics of p53, a natural tumor suppressor, in cancer cells whe ... more

    Chemical Exposures and the Brain: The Flint Water Crisis and More

    The water crisis gripping Flint, Michigan has exposed thousands of children to unsafe lead levels, triggering a federal emergency declaration and national conversation about basic public health protections. Lead can be toxic to the brain, and children can be particularly vulnerable. However ... more

More about Novartis